Navigation Links
Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
Date:12/16/2008

FDA to review Intermezzo(R) (zolpidem tartrate sublingual lozenge) as the first sleep aid specifically designed for the treatment of middle-of-the-night awakenings

PT. RICHMOND, Calif., Dec. 16 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual lozenge) has been accepted for review by the agency. Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

Glenn A. Oclassen, President and Chief Executive Officer of Transcept, commented, "Confirmation that the FDA has accepted the Intermezzo(R) NDA and has begun its review represents another important milestone in our efforts to gain FDA approval for Intermezzo(R), which we believe is positioned to be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. Based on an anticipated standard review process, we currently expect to receive a complete response letter regarding Intermezzo(R) in the fourth quarter of 2009 and to initiate the potential U.S. commercialization and launch in the first half of 2010, if Intermezzo(R) is approved."

The Intermezzo(R) NDA follows the successful completion of two Phase 3 clinical trials. The first Intermezzo(R) Phase 3 trial was a double-blind, placebo-controlled crossover sleep laboratory study of 82 patients, which Transcept believes to be among the largest reported sleep laboratory studies of its type. Results from the study dem
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
2. Transcept Pharmaceuticals Appoints Key Senior Executives
3. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014   BioTE Medical , a ... bio-identical hormone pellets, today announced the addition of ... company.   Dr. Rouzier is joining the BioTE Medical ... Dr. Rouzier was residency trained in Family ... a board certified emergency physician still practicing at ...
(Date:7/22/2014)... Rice Lake Weighing Systems ... NCSL International Workshop and Symposium July 28-31 in ... pressure instrumentation, OIML M1 weights, precision lab weights, ... sets, Essential Weights™. , NCSL International was formed ... solving the common problems faced by measurement and ...
(Date:7/22/2014)... 22, 2014  Neogen Corporation (NASDAQ: NEOG ... year, which ended May 31, increased 19% from the ... $28,158,000, compared to the prior year,s $27,190,000. Adjusted for ... per share in the current year were $0.76, compared ... income for the 2014 fiscal year established new all-time ...
(Date:7/22/2014)... and SHENZHEN, China ... Solutions Co., LTD, (BGI Tech), a subsidiary of ... the global launch of a new human whole ... platform. This newly offered service includes in-depth bioinformatics ... reduced prices until December 31, 2014. ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2Neogen reports 19% increase in annual revenues 2Neogen reports 19% increase in annual revenues 3Neogen reports 19% increase in annual revenues 4Neogen reports 19% increase in annual revenues 5Neogen reports 19% increase in annual revenues 6Neogen reports 19% increase in annual revenues 7Neogen reports 19% increase in annual revenues 8BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... MIGENIX Inc. (the,"Company" or "MIGENIX") (TSX: MGI; ... infectious diseases, reports financial results for the ... a corporate update on its programs,and other ... Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic ...
... decades-old drug to beat atherosclerotic plaques in research conducted ... , The scientists have found that drug-laced nanoparticles plus ... vessels that feed arterial plaques. Their results suggest that ... their growth, which could shrink or stabilize plaques. Although ...
... safe supply of drinking water for regions of the ... is rife. Writing in the International Journal of ... nanotubes could replace conventional materials in water-purification systems. , ... water will continue to grow as major global problems. ...
Cached Biology Technology:MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11Old and new therapies combine to tackle atherosclerosis 2Old and new therapies combine to tackle atherosclerosis 3Water purification down the nanotubes 2
(Date:7/22/2014)... research in the Journal of Clinical ... signaling and dopamine transporter function are linked ... Parkinsonism and attention deficit hyperactivity disorder (ADHD). ... critical basis for further exploration of how ... contribute to brain disorders" said Michelle Sahai, ...
(Date:7/22/2014)... that examined the survival rates of 12 different ... longline fishing operations found large differences in survival,rates ... and scalloped hammerhead being the most,vulnerable. The study, ... (UM) Rosenstiel School of,Marine and Atmospheric Science and ... provides,new information to consider for future conservation measures ...
(Date:7/22/2014)... Institute of Standards and Technology (NIST), working with ... technique for analyzing biological cells and tissues based ... technique is an advanced form of the widely ... signals that are 10,000 times stronger than obtained ... than obtained from comparable "coherent Raman" instruments, and ...
Breaking Biology News(10 mins):The dopamine transporter 2The dopamine transporter 3New study reveals vulnerability of sharks as collateral damage in commercial fishing 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3
... fossil tracks belonging to large, carnivorous dinosaurs have been ... Monash University and the Museum of Victoria (both in ... large dinosaurs were living in a polar environment during ... Antarctica and close to the South Pole. The ...
... triggered after specific engagement of foreign peptides (antigens) ... Cellular signaling pathways are responsible for the activation ... in T cells, which constitute a subgroup of ... in response to antigen stimulation. Malt1 is part ...
... team of Australian and Israeli researchers has discovered what ... event on Earth., An ancient light-sensitive gene has been ... for Coral Reef Studies (CoECRS) that appears to act ... corals across a third of a million square kilometres ...
Cached Biology News:Emory paleontologist reports discovery of carnivorous dinosaur tracks in Australia 2Key found to moonlight romance 2Key found to moonlight romance 3
... is an evolutionarily conserved form of cell ... The central component of this process ... caspases. These enzymes participate in a ... response to pro-apoptotic signals and result in ...
... DNA Visualizer Extraction Kit is manufactured for ... DNA damage byexposure to UV light. The ... is often used for DNA-cloning work. The ... bromide and exposure of UV light damages ...
... TargeTron(TM) Gene Knockout System provides optimized reagents ... disruption of bacterial genes by insertion of ... retrohoming ability of group II introns and ... the TargeTron group II intron for specific ...
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Biology Products: